Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

zibotentan

Known as: 3-Pyridinesulfonamide, N-(3-methoxy-5-methylpyrazinyl)-2-(4-(1,3,4-oxadiazol-2-yl)phenyl)-, N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pridine-3- sulfonamide 
An orally available selective antagonist of the endothelin-A (ET-A) receptor with potential antineoplastic activity. Zibotentan binds selectively to… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) has been revolutionized by the arrival of… Expand
  • figure 1
  • table 1
Is this relevant?
Highly Cited
2013
Highly Cited
2013
PURPOSE As part of the ENTHUSE (Endothelin A Use) program, the efficacy and safety of zibotentan (ZD4054), an oral specific… Expand
Is this relevant?
2013
2013
Background:Standard treatment options are limited for the management of non-metastatic castration-resistant prostate cancer (CRPC… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2013
2013
Endothelin 1 (ET-1) is overexpressed in cancer, contributing to disease progression. We previously showed that ET-1 stimulated… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
Ever since docetaxel was shown to be the first known agent to extend survival in men with metastatic castration-resistant… Expand
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Endothelin-1 and the endothelin A (ET(A) ) receptor have been implicated in prostate cancer progression in bone. This… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2012
2012
Epithelial ovarian cancer (eoc) is the leading cause of gynecologic cancer mortality worldwide. The drug-resistant nature of eoc… Expand
Is this relevant?
Highly Cited
2011
Highly Cited
2011
PURPOSE Emerging evidence suggests molecular and phenotypic association between chemoresistance and epithelial-mesenchymal… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2010
Highly Cited
2010
OBJECTIVES To report the final analysis of a Phase II trial, which investigated the safety and efficacy of the specific… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
2009
2009
SummaryPurpose To assess the maximum well-tolerated dose (MWTD), dose limiting toxicity (DLT), pharmacokinetics (PK) and… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?